Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hokuyaku Takeyama HoldingsSSE:3055 +1.67%56 EBITDA Margin % is 1.12% as of Mar. 2026, which is 38% below its 10-year median of 1.82. GuruFocus rates SSE:3055 with a GF Score™ of 56/100 and a GF Value™ of 円956.39 (Fairly Valued). The stock has 4 warning signs investors should review. Among 117 Medical Distribution companies, Hokuyaku Takeyama Holdings ranks worse than 80.34% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Hokuyaku Takeyama Holdings EBITDA Margin % Related Terms
Hokuyaku Takeyama Holdings EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SSE:3055 vs MCK, CAH, COR: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Hokuyaku Takeyama Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hokuyaku Takeyama Holdings EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Hokuyaku Takeyama Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Hokuyaku Takeyama Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hokuyaku Takeyama Holdings (SSE:3055) has a EBITDA Margin % of 1.12% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hokuyaku Takeyama Holdings and its competitors. This is 38% below median its historical median of 1.82. Over the past decade, Hokuyaku Takeyama Holdings' EBITDA Margin % has ranged from 1.38 to 2.07. According to the industry distribution chart, Hokuyaku Takeyama Holdings ranks #94 out of 117 companies in the Medical Distribution industry, placing it in the top 80.3%.
Is Hokuyaku Takeyama Holdings' EBITDA Margin % too high?
Hokuyaku Takeyama Holdings' current EBITDA Margin % of 1.12% is 38% below median its 10-year median of 1.82. Over the past 10 years, this metric has ranged from a low of 1.38 to a high of 2.07. The Medical Distribution industry median EBITDA Margin % is 4.20. Hokuyaku Takeyama Holdings' value of 1.12% is 73.3% below this industry median. Based on the distribution chart, Hokuyaku Takeyama Holdings ranks #94 out of 117 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Hokuyaku Takeyama Holdings has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Hokuyaku Takeyama Holdings' EBITDA Margin % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Hokuyaku Takeyama Holdings ranks #94 out of 117 companies for EBITDA Margin %. This places Hokuyaku Takeyama Holdings in the lower half of its industry. The industry median EBITDA Margin % is 4.20. Hokuyaku Takeyama Holdings' value of 1.12% is 73.3% below this benchmark. Historically, Hokuyaku Takeyama Holdings' own EBITDA Margin % has ranged from 1.38 to 2.07 over the past decade. While the company's 10-year median is 1.82 vs. the industry median of 4.20, Hokuyaku Takeyama Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.20, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hokuyaku Takeyama Holdings's current EBITDA Margin % of 1.12% is 73.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hokuyaku Takeyama Holdings and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hokuyaku Takeyama Holdings's current EBITDA Margin % is 1.12%, which is 38% below median its own 10-year median of 1.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hokuyaku Takeyama Holdings stock overvalued right now?
Based on GuruFocus' analysis, Hokuyaku Takeyama Holdings (SSE:3055) is currently considered Fairly Valued. The stock's GF Value™ is 円956.39, compared to a current price of 円912.00 — trading 4.6% below its estimated fair value. The current EBITDA Margin % is 1.12%, which is 38% below median its 10-year median of 1.82 and 73.3% below the Medical Distribution industry median of 4.20. Hokuyaku Takeyama Holdings' overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Hokuyaku Takeyama Holdings (SSE:3055), the current EBITDA Margin % is 1.12% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hokuyaku Takeyama Holdings (SSE:3055) Overvalued in 2026?
Based on GuruFocus' analysis, Hokuyaku Takeyama Holdings stock appears to be undervalued.
The current stock price of 円912.00 is trading 4.6% below its estimated GF Value™ of 円956.39.
GuruFocus considers Hokuyaku Takeyama Holdings to be Fairly Valued.
Key valuation signals for SSE:3055:
EBITDA Margin %: 1.12% (38% below median its 10-year median of 1.82)
GF Value™: 円956.39 vs. price of 円912.00 (4.6% below fair value)
Industry Position: 73.3% below the Medical Distribution median (#94 of 117)
No single metric tells the full story. See the SSE:3055 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hokuyaku Takeyama Holdings Inc is a medical device wholesaler. The company also distributes ethical drugs and general-purpose medicines. It offers repair services for medical instruments and manages real estate for physics and chemistry instruments.
56GF Score
Get the complete analysis for SSE:3055
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SSE:3055 has been successfully added to your 
